Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).
Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).
复制标题
DOI：
10.1007/s10549-011-1725-6
复制
发表时间：
2011-12
影响因子：
3.8
通讯作者：
Miller, Kathy
中科院分区：
文献类型：
--
作者：
Cella, David;Wang, Molin;Wagner, Lynne;Miller, Kathy
关键词：
本研究旨在检查接受紫杉醇或紫杉醇+贝伐珠单抗E2100治疗的转移性乳腺癌女性患者的健康相关生活质量（HRQL）。试验参与者（N = 670）在治疗前以及治疗4个周期和8个周期后完成了癌症治疗功能评估-乳腺（FACT-B），以评估HRQL和乳腺癌特异性问题。在仅接受紫杉醇治疗的患者中观察到FACT-B评估缺失的比例显著更高，原因是至死亡时间更快。为了解释这种缺失数据的不可验证模式，我们使用两阶段模型联合建模纵向HRQL结局和至不可验证脱落的时间，进行了生存调整HRQL分析。在4个和8个治疗周期后，评估HRQL的FACT评分没有差异;然而，在接受紫杉醇+贝伐珠单抗治疗的患者中，在4个和8个治疗周期后，9项乳腺癌量表的平均评分显著更高。治疗组间FACT-B总分无差异。从患者的角度来看，添加贝伐珠单抗与额外的副作用负担无关，并且与乳腺癌特异性问题的更大减少相关。未发现其他差异。
The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.
登录
查看更多内容
影响因子：
2
作者：
Fitzmaurice, GM;Laird, NM;Shneyer, L
通讯作者：
Shneyer, L
影响因子：
158.5
作者：
Miller, Kathy;Wang, Molin;Davidson, Nancy E.
通讯作者：
Davidson, Nancy E.
影响因子：
45.3
作者：
Sledge, GW;Neuberg, D;Wood, WC
通讯作者：
Wood, WC
影响因子：
2
作者：
Schluchter, MD;Greene, T;Beck, GJ
通讯作者：
Beck, GJ
影响因子：
45.3
作者：
Brady, MJ;Cella, DF;Shiomoto, G
通讯作者：
Shiomoto, G